. Association of Race and Ethnicity With Dementia. JAMA. 2022 Apr 19;327(15):1454-1455. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. Another consideration in improving trial diversity is social and structural determinants to health that impact early screening and diagnosis of patients who are historically minoritized. A consideration is the patient's access to appropriate and quality care and ability to receive referrals for ADRD screening and treatment. A key aspect that may impact ADRD diagnosis in patients of color may also relate to discrimination, socioeconomic status, insurance status, educational level, and living environment. I often wonder if we should consider measuring health disparities in the same way that we measure other biomarkers for ADRD.

    View all comments by Joyce Balls-Berry

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Diversity: FDA Guidance and New Data on Incidence/Biomarkers by Race